ProQinase GMBH was established as a wholly owned subsidiary of the Tumor Biology Centre (TBC), Freiburg, in April 2001 to commercialize the centre's research on protein kinases. During their years of basic research at TBC, ProQinase's scientists have developed extensive know-how in the protein kinase arena and have established a range of tools and assays to identify, produce, manipulate and screen protein kinases' activities. These tools and assays now constitute the Integrated Technology Platform Protein Kinases that ProQinase is commercializing through a hybrid business model. The company will apply the platform technology to its own in-house drug discovery and development activities and also make it available to external clients on a fee-for-service basis.
You may also be interested in...
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.